This series highlights the evolving role of BTK inhibitors for the treatment of CLL.
EP. 1: Weighing the Impact of Long-term Safety and Efficacy Data for Ibrutinib in the Treatment of CLL
Continued data for the first-generation BTK inhibitor have demonstrated its expanding utility amid a growing treatment arsenal.
EP. 2: Jennifer A. Woyach, MD, Reflects on the Changing BTK Inhibitor Landscape
With the treatment landscape rapidly developing with the approval of new agents and the investigation of various combination regimens, understanding the individual profiles of each agent will aid treatment selection.
EP. 3: Emerging BTK-based Combination Approaches for CLL: Ibrutinib Plus Venetoclax
Findings suggest that combination regimens may extend overall and progression-free survival.
EP. 4: Envisioning the Role of Combination Therapy in the Treatment of CLL: A Q&A With Philip Thompson, MB, BS
Targeting different pathways may dramatically reduce the risk of resistance emergence and improve outcomes.
EP. 5: Expert Perspective on RESONATE-2 Findings and the Value of Long-term Data for Single-Agent BTK Inhibitors
Paul M. Barr, MD discusses key takeaways from the follow-up data and reflects on the clinical and practical implications of the 7-year findings.
EP. 6: Exploring the Utility of a Next-Generation BTK Inhibitor for the Treatment of Patients With Chronic Lymphocytic Leukemia
Zanubrutinib has demonstrated clinical benefit as both a monotherapy and in combination with other agents for the treatment of patients with chronic lymphocytic leukemia.
2 Commerce Drive Cranbury, NJ 08512